ST Shuangcheng: Injection pantoprazole sodium ANDA obtained US FDA marketing authorization.

ST Shuangcheng Announcement: The company has recently received a notification from the US Food and Drug Administration that the abbreviated new drug application for injection pantoprazole sodium submitted by the company to the US FDA has been approved for market authorization. Injection pantoprazole sodium is suitable for duodenal ulcers, gastric ulcers, acute gastric mucosa lesions, complex gastric ulcers, and other acute upper gastrointestinal bleeding. The approval of the company's injection pantoprazole sodium ANDA by the US FDA signifies that the safety and efficacy of the injection pantoprazole sodium developed and manufactured by the company have reached the original research level, demonstrating the company's international level of research and production. This also enriches the company's international sales product pipeline, further promoting the company's internationalization process, and has an important positive impact on enhancing the company's international influence and future business performance.